biotech – Page 2 – media

Vertex Pharma Doubles Cystic Fibrosis Research Facility

Boston-based Vertex Pharmaceuticals has more than doubled their research facility in San Diego where they first discovered their key Cystic Fibrosis Drug adding more than 90000 sq ft. to it. The total facility will be now 170,000 sq. ft improving the pharma giant's capability to achieve the next generation of blockbusters.
- Source: Fierce Biotech
- 610
- June 20, 2018
biotech Company Insights
Syncona Once More Proves Commitment to Freeline in Series B Funding Round

Syncona has once again proven its commitment to gene therapy start-up, Freeline Therapeutics with a £85 million investment from the £88 million series B funding round. Freeline’s main focus is on gene therapy for Haemophilia B and Farby disease and this latest cash injection ensures Syncosa’s majority stake in the startup.
- Source: Fierce Biotech
- 657
- June 20, 2018
biotech Company Insight funding hemophilia
Patient Capital Program for Start-ups of £2.5 Billion Created by U.K.

In an innovative push to help biotech start-ups in Britain become independent medium-sized enterprises, the U.K. set up a £2.5 billion patient capital program.
- Source: Fierce Biotech
- 704
- June 15, 2018
biotech digital health Market Views start ups
Anti-Aging Stratup Juvenescence Raises $50 Million for New Project

The Isle of Man-based anti-aging biotech company is focusing on developing therapeutics for human longevity by partnering, creating, and investing in companies with anti-aging related projects.
- Source: Fierce Biotech
- 490
- June 13, 2018
biotech Company Insight funding
Accent raised $40 Million to Develop Epitranscriptomics Studies

Cambridge, Mass.-based Biotech startup Accent Therapeutics announced $40 million A series funding to develop cancer treatment based on epitranscriptomics, an RNA-modifying protein (RMPs) which have been connected to recent cancer studies.
- Source: Ddu
- 674
- May 21, 2018
biotech cancer Company Insight DNA
Biotechnology Company Abpro postpones $69M IPO

According to reports, the biotechnology company Abpro has rescheduled its $96 million IPO, delaying a capital infusion it hoped would support the first clinical trials of its lead product candidates over the next year.
- Source: Ddu
- 612
- May 14, 2018
biotech Company Insights IPO
De Rothschild raises €345M Europe-skewed life science fund

Edmond De Rothschild Investment Partners has raised €345 million ($430 million) for its latest fund. The haul makes BioDiscovery 5 the largest fund dedicated to biotechs and medical devices in Europe and tees up Edmond De Rothschild to invest in 15 to 17 companies.
- Source: FierceBiotech
- 583
- February 8, 2018
biotech Company Insight medical device

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.